Agalsidase Beta

In the US, Agalsidase Beta (agalsidase beta systemic) is a member of the drug class lysosomal enzymes and is used to treat Fabry Disease.

US matches:

• Agalsidase Beta


• Agalsidase beta Intravenous

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

A16AB04

CAS registry number (Chemical Abstracts Service)

0104138-64-9

Therapeutic Category

Enzyme, replacement therapy

Chemical Name

Alpha-galactosidase (human clone, lambdaAG18 isoenzyme A subunit protein moiety reduced), glycoform beta (WHO)

Foreign Names

• Agalsidasum beta (Latin)
• Agalsidase beta (German)
• Agalsidase beta (French)
• Agalsidasa beta (Spanish)

Generic Names

• Alpha galactosidase A (IS)
• Fabrase (IS)
• Recombinant human alpha-galactosidase A (IS)

Brand Names

• Fabrazyme
  Genzyme, Austria; Genzyme, Australia; Genzyme, Belgium; Genzyme, Canada; Genzyme, Switzerland; Genzyme, Czech Republic; Genzyme, Germany; Genzyme, Denmark; Genzyme, Spain; Genzyme, Finland; Genzyme, France; Genzyme, Greece; Genzyme, Hungary; Genzyme, Israel; Genzyme, Italy; Genzyme, Luxembourg; Genzyme, Netherlands; Genzyme, Norway; Genzyme, Sweden; Genzyme, Slovenia; Genzyme, Slovakia; Genzyme, United States; Genzyme Nippon, Japan; Medical Intertrade, Croatia (Hrvatska)

International Drug Name Search

Glossary

IS	Inofficial Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.